Scientific Committee on Oceanic Research

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Tuesday, October 31, 2023
Kidney, Frankfurt Stock Exchange, Patient, Hemofiltration, Research, FME, Intelligence, III, HDF, Assessment of kidney function, AVF, Big data, Fatigue, HD, American Society of Nephrology, Saskatchewan River Sturgeon Management Board, Arteriovenous fistula, FX, Health, Society, Artificial intelligence, Dialysis, PO4, PSM, COVID-19, ASN, Machine learning, Congress, Fresenius Medical Care, FKC, RBV, Creatinine, Scientific Committee on Oceanic Research, FMS, Peritoneum, IDS, Data science, Pharmaceutical industry, Medical device, Hemodialysis, Nephrology

Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.

Key Points: 
  • Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.
  • Scientific and medical experts from across Fresenius Medical Care will present research related to many important topics in kidney disease care.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Pew Bertarelli: Timeline for Krill Conservation Measures Confirmed

Retrieved on: 
Friday, October 27, 2023
Antarctic Treaty System, MPAS, Science, Commission, Whale, Conservation, Antarctic Peninsula, Bertarelli Foundation, MPA, The Pew Charitable Trusts, News, Carbon, Convention for the Conservation of Antarctic Marine Living Resources, Fishery, Multimedia, Maud Rise, Breeding, Season, Travel, Animal, Pew, CCAMLR, Scientific Committee on Oceanic Research, European, Whaling, Aquaculture, Antarctica, Antarctic, Nature, Weddell Sea

HOBART, Australia, Oct. 27, 2023 /PRNewswire/ -- The Pew Bertarelli Ocean Legacy Project today praised delegates from 26 nations and the European Union for marking progress toward harmonizing an updated krill fishery management plan with Southern Ocean protections along the Antarctic Peninsula.

Key Points: 
  • Tethering these two krill conservation efforts allows CCAMLR to fulfill its mandate to prevent irreversible impacts on the Southern Ocean ecosystem from human activities such as fishing.
  • Over the past decade, industrial krill fishing has become increasingly concentrated in areas along the Antarctic Peninsula, affecting predators that feed in those same areas.
  • Without protection for large areas of the Southern Ocean and new fisheries measures, we will all suffer the consequences."
  • The Pew Charitable Trusts addresses the challenges of a changing world by illuminating issues, creating common ground, and advancing ambitious projects including the need for effective marine conservation.

Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors

Retrieved on: 
Wednesday, October 18, 2023
Storm, Biomedical Advanced Research and Development Authority, Global health, United States Army Nurse Corps, Certification, Civilization, Defense Advanced GPS Receiver, United States Army War College, Medicine, Kosovo Force, Combat support hospital, RN, Commanding officer, Health, Development, American Public University System, Disease, BioBridge Global, RET, University of Kansas, USAMRIID, University, Fort Detrick, National security, Pandemic, United States Army Medical Research and Development Command, ROTC, Infection, Texas Desert Shield-Desert Storm Campaign Medal, BSN, MSN, Scientific Committee on Oceanic Research, Operation New Dawn, 67th Combat Support Hospital (United States), Nursing, Operation, DARPA

Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.

Key Points: 
  • Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
  • This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.
  • "I am pleased to welcome General Holcomb's leadership in national security and patient care to Maxwell's board as we approach human trials next year," said Maxwell Biosciences Chairman and CEO Joshua McClure.
  • "General Holcomb is a highly patient-focused medical professional with decades of deep respect within the global and national security biodefense communities.

WISeKey Demonstrated WISe.ART’s Commitment to Sustainability at the Phygital Sustainability Expo® in Rome, Italy

Retrieved on: 
Thursday, July 13, 2023
Crypto, Lazio, COP28, Partnership, Internet of things, Partner, Tree, Sustainable Development Goal 9, WIHN, Kaufmann, Scientific Committee on Oceanic Research, CCA, Carbon, Element, Sustainable Development Goals, WKEY, Lamborghini, 2016 United Nations Climate Change Conference, Economic development, Ecology, Conference, Tourism

WISeKey Demonstrated WISe.ART’s Commitment to Sustainability at the Phygital Sustainability Expo® in Rome, Italy

Key Points: 
  • WISeKey Demonstrated WISe.ART’s Commitment to Sustainability at the Phygital Sustainability Expo® in Rome, Italy
    Rome, Italy, July 12, 2023 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions, announced today that during its participation at the Phygital Sustainability Expo in Rome, it demonstrated WISe.ART’s unwavering commitment to sustainability.
  • Phygital Sustainability Expo is Italy's premier gathering focused on fostering the sustainable transformation of fashion and design brands made in Italy.
  • Together, the Sustainable Fashion Innovation Society and the Phygital Sustainability Expo spearhead the ecological transition of Italy's fashion and design sector.
  • For more information about the Sustainable Fashion Innovation Society and the Phygital Sustainability Expo, please visit: sustainablefashioninnovation.org

AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline

Retrieved on: 
Wednesday, April 12, 2023
Science, Nerve, AAN, Neurodegenerative disease, Survival, Clinical trial, ALS, American Academy, Scientific Committee on Oceanic Research, Department of Neurology, Xuanwu hospital, Doctor of Philosophy, RESULTS, Trial of the century, Teaching hospital, Medical school, OF, Euronext, CAFS, Patient, Riluzole, Observation, Neuro, American Academy of Neurology, Pharmaceutical industry, Medical device, MD, Neurology

The AAN Annual Meeting is the world’s premier neurology meeting, attracting over 10,000 neurology professionals from around the globe.

Key Points: 
  • The AAN Annual Meeting is the world’s premier neurology meeting, attracting over 10,000 neurology professionals from around the globe.
  • The title of this presentation is ‘Masitinib Shows Prolonged Survival in Amyotrophic Lateral Sclerosis (ALS) Patients with Mild or Moderate Disease Severity at Baseline’.
  • Included in this presentation are the long-term survival data that showed a significantly prolonged survival of 25 months in favor of masitinib for patients with non-severe disease severity at baseline.
  • Of note, this latter population includes all patients regardless of baseline progression rate and encompasses about 80% of the overall AB10015 study population.

AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy

Retrieved on: 
Tuesday, February 28, 2023
ADAS-Cog, Safety, Scientific Committee on Oceanic Research, Memantine, B cell, ALS, ADAS, Disease, Drug development, Enzyme inhibitor, Marine Institute of Memorial University of Newfoundland, Research, Patient, Cognition, Science, Multiple sclerosis, Memory, Journal, Vaccine, Fine chemical, MD

Results showed that masitinib at 4.5 mg/kg/day can benefit patients by significantly slowing cognitive deterioration relative to placebo.

Key Points: 
  • Results showed that masitinib at 4.5 mg/kg/day can benefit patients by significantly slowing cognitive deterioration relative to placebo.
  • There are very limited treatment options for patients with mild-to-moderate Alzheimer’s disease and to date no approved disease modifying therapy encompasses this later-stage Alzheimer’s disease population.
  • The safety of masitinib as an adjunct to cholinesterase inhibitor and/or memantine was acceptable and consistent with its known tolerability profile.
  • It is noteworthy that this result is in the context of a relative elderly population (average age of about 73 years) with comorbidities.